Fostamatinib Trial for Lung Transplant Patients with Donor-Specific Antibodies
A trial is underway to evaluate the safety and tolerability of fostamatinib in lung transplant patients with donor-specific antibodies.
Asset / Drug
Drug and asset intelligence for fostamatinib with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Spleen Tyrosine Kinase Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.